Dr. Greene is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3400 Spruce St
Philadelphia, PA 19104Phone+1 215-662-6503
Summary
- Dr. Mark Greene is a healthcare professional based in Philadelphia, PA, specializing in Internal Medicine . He completed his education at the University of Manitoba, including a PhD in Immunology. Dr. Greene serves as the John Eckman Professor of Medical Science at the Hospital of the University of Pennsylvania. His research experience includes work with proto-oncogene proteins, and he has several publications focusing on HER2 cancer therapy and structural immunology, with notable citations. Over the years, he has received several honors such as the Fellow of Lincoln College from Oxford University and the BCRF Breast Cancer Research Award. He discovered targeted therapy of p185Neu and the therapy of HER2 tumors with single or dual targeted monoclonal. His discovery of AHNP ( based on the crystal structure of the antiHER2 monoclonal) and is able to be coupled to different molecules to enter HER2 transformed cells
Education & Training
- University of ManitobaPhD, Immunology, 1973 - 1977
- University of ManitobaClass of 1972
- University of ManitobaBachelor's, 1966 - 1968
Certifications & Licensure
- PA State Medical License 1985 - 2024
- MA State Medical License 1975 - 2023
- Fellow of the Royal College of MedicineInternal Medicine
Awards, Honors, & Recognition
- Fellow Lincoln College Oxford University, 2010
- Geurin Chair Cedars-Sinai, 2010
- Dsc, Honoris causa, MAN 2009
- Join now to see all
Publications & Presentations
PubMed
- 2 citationsF77 antigen is a promising target for adoptive T cell therapy of prostate cancer.Payal Grover, Selene Nunez-Cruz, John Leferovich, Tyra Wentz, Atrish Bagchi
Biochemical and Biophysical Research Communications. 2023-11-05 - 3 citationsDual kinase inhibitor for EGFR mutants and ErbB2 limit breast cancer.Peeyush N Goel, Hongtao Zhang, Ramachandran Murali, Cai Zheng, Mei Q Ji
Biochemical and Biophysical Research Communications. 2023-04-09 - 2 citationsChallenges in Detection of Serum Oncoprotein: Relevance to Breast Cancer Diagnostics.Justin Lengfeld, Hongtao Zhang, Steven Stoesz, Ramachandran Murali, Franklin Pass
Breast Cancer. 2021-10-14
Journal Articles
- Suppression by human FOXP3+ regulatory T cells requires FOXP3-TIP60 interactionsBin Dhuban K, d'Hennezel E, Nagai Y, Xiao Y, Shao S, Istomine R, Alvarez F, Ben-Shoshan M, Ochs H, Mazer B, Li B, Sekine C, Berezov A, Hancock W, Torgerson TR, Greene ..., Sci Immunol, 1/1/2017
- Atomic Description of the Immune Complex involved in Heparin-Induced Thrombocytopenia (HIT)Cai Z, Yarovoi SV, Zhu Z, Rauova L, Hayes V, Lebedeva T, Liu Q, Poncz M, Arepally G, Cines DB, and Greene MI, Nature Communications, 1/22/2015
- Join now to see all
Books/Book Chapters
Press Mentions
- Dr. Peter Nowell, Who Helped Transform Cancer Research, Dies at 88January 11th, 2017
- Navidea Reports First Quarter 2016 Financial ResultsMay 17th, 2016
Grant Support
- Inhibition Of Heteromeric ERBB KinasesNational Cancer Institute2011–2012
- Receptor Mediated Breast Cancer TherapyNational Cancer Institute2001–2012
- Immune Chemistry And Therapeutic Features Of FOXP3National Institute Of Allergy And Infectious Diseases2008–2011
- FOXP3 And Immune RegulationNational Institute Of Allergy And Infectious Diseases2008–2011
- Administrative CoreNational Institute Of Allergy And Infectious Diseases2008–2011
- Immunobiology Of P185 ReceptorNational Cancer Institute1992–2011
- Receptor-Mediated Effects On Oligodendrocyte Phenotype And DiseaseNational Institute Of Neurological Disorders And Stroke2007
- Viral Receptors Of The Visual Nervous SystemNational Institute Of Neurological Disorders And Stroke2004–2007
- Training In Cancer ImmunopathobiologyNational Cancer Institute2003–2007
- Receptor Mediated Efffects On Oligodendrocyte PhenotypeNational Institute Of Neurological Disorders And Stroke2004–2006
- Novel Approaches To Cancer TherapyNational Cancer Institute2002–2005
- Receptor-Mediated Effects On Oligodendrocyte PhenotypeNational Institute Of Neurological Disorders And Stroke2003
- Core--StructuralNational Cancer Institute2002
- Immunobiology Of Antireceptor Receptor InteractionsNational Eye Institute1991–2001
- Receptor/Ligand Interactions Of Developing OligodendrocytesNational Institute Of Neurological Disorders And Stroke1996–2000
- Training Program In Immunobiology Of The EyeNational Eye Institute1991–2000
- Molecular Regulation Of T Cell Apoptosis &AutoimmunityNational Institute Of Allergy And Infectious Diseases1994–1996
- Molecular Regulation Of Neoplastic And Normal GrowthNational Cancer Institute1992–1996
- Immunobiology Of Antireceptor-Receptor InteractionsNational Eye Institute1995
- Cellular And Molecular Regulation Of Ocular ImmunityNational Eye Institute1993–1995
- Facstar-Plus Dual Laser Flow CytometerNational Center For Research Resources1993
- Characterization Of The Mammalian Reovirus ReceptorNational Eye Institute1989–1993
- Cellular &Molecular Regulation Of Ocular ImmunityNational Eye Institute1986–1992
- Immunobiology Of Normal And Neoplastic LymphocytesNational Cancer Institute1986–1991
- Immunobiology Of Antireceptor-Receptor InteractionsNational Institute Of Allergy And Infectious Diseases1986–1990
- Characterization Of The Mammalian Reovirus ReceptorNational Institute Of Allergy And Infectious Diseases1986–1988
- Manipulation Of Regulatory T Cell SpecificitiesNational Cancer Institute1986–1988
- Immunobiology Of Normal &Transformed CellsNational Cancer Institute1987
- Suppressor T Cells In Hapten Specific ImmunityNational Institute Of Allergy And Infectious Diseases1985
Research History
- Ph.DImmunology/immunochemistry1973 - 1977
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: